HK1072905A1 - Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof - Google Patents

Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof

Info

Publication number
HK1072905A1
HK1072905A1 HK05106618.4A HK05106618A HK1072905A1 HK 1072905 A1 HK1072905 A1 HK 1072905A1 HK 05106618 A HK05106618 A HK 05106618A HK 1072905 A1 HK1072905 A1 HK 1072905A1
Authority
HK
Hong Kong
Prior art keywords
derivatives
carboxylic acids
sub
site
action
Prior art date
Application number
HK05106618.4A
Other languages
English (en)
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of HK1072905A1 publication Critical patent/HK1072905A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
HK05106618.4A 2002-05-14 2005-08-02 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof HK1072905A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38064102P 2002-05-14 2002-05-14
PCT/US2003/014948 WO2003097564A2 (en) 2002-05-14 2003-05-12 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof

Publications (1)

Publication Number Publication Date
HK1072905A1 true HK1072905A1 (en) 2005-09-16

Family

ID=29549994

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05106618.4A HK1072905A1 (en) 2002-05-14 2005-08-02 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof

Country Status (17)

Country Link
US (2) US7355047B2 (xx)
EP (1) EP1503759B1 (xx)
JP (1) JP4532263B2 (xx)
KR (1) KR20040107525A (xx)
CN (1) CN1652784A (xx)
AT (1) ATE417613T1 (xx)
AU (1) AU2003229043B2 (xx)
BR (1) BR0309965A (xx)
CA (1) CA2484308A1 (xx)
DE (1) DE60325347D1 (xx)
DK (1) DK1503759T3 (xx)
ES (1) ES2319176T3 (xx)
HK (1) HK1072905A1 (xx)
IL (1) IL164734A0 (xx)
MX (1) MXPA04011156A (xx)
NZ (1) NZ536061A (xx)
WO (1) WO2003097564A2 (xx)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
DE60325347D1 (de) * 2002-05-14 2009-01-29 Univ California Substituierte chinoloncarbonsäuren, ihre derivate, wirkungsort und anwendungen
DE102004004971B3 (de) * 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel
US7470706B2 (en) 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
AU2005240657A1 (en) * 2004-05-06 2005-11-17 The Regents Of The University Of California Substituted enaminones, their derivatives and uses thereof
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
LT2489659T (lt) 2004-06-24 2018-03-26 Vertex Pharmaceuticals Incorporated Atp rišančios kasetės transporterių moduliatoriai
CA2605384A1 (en) * 2005-04-11 2006-10-19 F. Hoffman-La Roche Ag (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines
CN101171238B (zh) * 2005-05-04 2010-12-15 弗·哈夫曼-拉罗切有限公司 对5-ht受体具有活性的(3,4-二氢-喹唑啉-2-基)-(2-芳氧基-乙基)胺
CA2631917A1 (en) * 2005-12-05 2007-06-14 Merck & Co., Inc. Quinolone m1 receptor positive allosteric modulators
US20090105272A1 (en) * 2005-12-24 2009-04-23 Grootenhuis Peter D J Prodrugs of modulators of ABC transporters
RS60205B1 (sr) 2005-12-28 2020-06-30 Vertex Pharma Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida
PL2383271T3 (pl) * 2006-03-13 2013-12-31 Kyorin Seiyaku Kk Aminochinolony jako inhibitory GSK-3
EP2064185B1 (en) * 2006-08-10 2011-06-08 Ferrer Internacional, S.A. 1h-quinolin-4-one compounds, with affinity for the gaba receptor, processes, uses and compositions
EP1886996A1 (en) * 2006-08-10 2008-02-13 Ferrer Internacional, S.A. 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
EP2074123B1 (en) * 2006-10-16 2012-12-05 Bionomics Limited Novel anxiolytic compounds
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
WO2009040377A2 (en) * 2007-09-27 2009-04-02 Ge Healthcare Limited Imaging agents
WO2010047990A1 (en) * 2008-10-23 2010-04-29 Merck Sharp & Dohme Corp. Fused heterocyclic m1 receptor positive allosteric modulators
KR101955863B1 (ko) 2009-03-20 2019-03-07 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
US20120093917A1 (en) * 2009-04-02 2012-04-19 Robert Hromas Metnase and intnase inhibitors and their use in treating cancer
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
JP2014510065A (ja) 2011-03-02 2014-04-24 バイオノミックス リミテッド 治療薬としての新規な小分子
WO2012116410A1 (en) * 2011-03-02 2012-09-07 Bionomics Limited Methods of treating a disease or condition of the central nervous system
US9133188B2 (en) 2011-05-12 2015-09-15 Bionomics Limited Methods for preparing naphthyridines
NZ629199A (en) 2012-02-27 2017-01-27 Vertex Pharma Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
RU2749213C2 (ru) 2014-10-07 2021-06-07 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
CN107501107A (zh) * 2017-09-26 2017-12-22 兰亚朝 喹诺酮药物的中间体合成方法
CN111269131B (zh) * 2020-03-12 2021-12-28 江苏飞宇医药科技股份有限公司 以三正丙胺为吸酸剂制备环丙乙酯胺化物的工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1433774A (en) * 1973-02-26 1976-04-28 Allen & Hanburys Ltd Heterocyclic compounds apparatus for conveying articles
JPS5715760B2 (xx) * 1974-06-11 1982-04-01
US4390541A (en) * 1980-12-19 1983-06-28 Lilly Industries Limited Quinolone derivatives and their use in a method of controlling an immediate hypersensitivity disease
US6248739B1 (en) * 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
ES2235883T3 (es) * 1999-05-06 2005-07-16 Neurogen Corporation 4-oxo-quinolino-3-carboxamidas sustituidas: ligandos de receptores cerebrales gaba.
GB0127349D0 (en) * 2001-11-14 2002-01-02 Glaxo Group Ltd Macrolides
DE60325347D1 (de) * 2002-05-14 2009-01-29 Univ California Substituierte chinoloncarbonsäuren, ihre derivate, wirkungsort und anwendungen

Also Published As

Publication number Publication date
ES2319176T3 (es) 2009-05-05
ATE417613T1 (de) 2009-01-15
KR20040107525A (ko) 2004-12-20
NZ536061A (en) 2008-09-26
JP2005535592A (ja) 2005-11-24
WO2003097564A3 (en) 2004-02-26
US20080176897A1 (en) 2008-07-24
CN1652784A (zh) 2005-08-10
JP4532263B2 (ja) 2010-08-25
EP1503759B1 (en) 2008-12-17
IL164734A0 (en) 2005-12-18
AU2003229043A1 (en) 2003-12-02
DK1503759T3 (da) 2009-04-14
WO2003097564A2 (en) 2003-11-27
EP1503759A2 (en) 2005-02-09
DE60325347D1 (de) 2009-01-29
US7355047B2 (en) 2008-04-08
AU2003229043B2 (en) 2008-12-04
CA2484308A1 (en) 2003-11-27
US20060178516A1 (en) 2006-08-10
EP1503759A4 (en) 2006-02-15
MXPA04011156A (es) 2005-02-17
BR0309965A (pt) 2005-03-01

Similar Documents

Publication Publication Date Title
HK1072905A1 (en) Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof
UA85711C2 (ru) Замещенные енаминоны, их производные и их применение
EP1862457A3 (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors
EP2292259A3 (en) Complement receptor 2 targeted complement modulators
WO2000045799A3 (de) Verwendung von substituierten isoxazolcarbonsäuren und derivaten und neue stoffe
PL369396A1 (en) Novel fluorene carboxylic acid esters, methods for the production thereof, and use of the same as pharmaceuticals
AU2003210172A1 (en) Novel fluorene carboxylic acid esters, methods for the production thereof, and use of the same as pharmaceuticals
NO20072767L (no) Gabapentin prodrug vedvarende frigivelse orale doseringsformer
AU2002316437A1 (en) Pyrrolidines as dipeptidyl peptidase inhibitors
TR200103493T2 (tr) Metaloproteaz önleyicileri
AP2005003418A0 (en) Alpha substituted carboxylic acids as ppar modulators.
WO2004031374A3 (en) Secondary binding site of dipeptidyl peptidase iv (dp iv)
DK0678087T3 (da) Forbindelser med selektiv aktivitet til retinoid-X-receptorer og metoder til modulering af processer medieret af retinoid-X
HK1050216B (zh) 產生對映體純正α-替代羧酸的方法
AU2003304226A1 (en) Inhibition of rosin crystallization
AU6689900A (en) 3-arylsulfonyl-2-(substituted methyl)propanoic acid derivates as matrix metalloproteinase inhibitors
HK1042705A1 (en) Crystal modification B of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo (4.3.0)nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid.
DE60216083D1 (de) (OXOPYRAZOLOi1,5AöPYRIMIDIN-2-YL) ALKYLCARBONSÄUREAMIDE
BG104801A (en) Indole-2,3-dione-3-oxime derivatives for therapeutical use
AU2003226755A1 (en) Carboxylic acid amides
WO2003045917A3 (en) Ccr-3 receptor antagonists vii
MXPA03002047A (es) Fenilciclohexanocarboxamidas substituidas y su uso.
AU2001244211A1 (en) Method for producing carboxylic acid benzyl esters
NO20014059L (no) Krystallmodifikasjon D av 8-cyano-1-cyklopropyl-7-(1S,6S-2,8- diazabicyklo-/4.3.0/-nonan-8-yl)-6-fluor-1,4-dihydro-4-okso-3-kinolinkarboksylsyre
EG23429A (en) Novel a-oxygenated or a-thiolated carboxylic acid phenethylamide derivatives.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130512